T-cell acute lymphoblastic leukemia with co-expression of CD56, CD34, CD117 and CD33: A case with poor prognosis
- Authors:
- Rafet Eren
- Ceyda Aslan
- Osman Yokuş
- Mehmet Hilmi Doğu
- Elif Suyani
View Affiliations
Affiliations: Department of Hematology, Istanbul Training and Research Hospital, Fatih, 34098 Istanbul, Turkey
- Published online on: June 13, 2016 https://doi.org/10.3892/mco.2016.927
-
Pages:
331-332
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
T-cell acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy, accounting for ~25% of all adult cases of ALL. We herein report a case of T-cell ALL exhibiting aberrant CD34, CD56, CD33 and CD117 expression in addition to T‑cell markers, which did not respond to induction treatment. A 55‑year‑old woman was admitted to our hospital with a sore throat unresponsive to medication for 1 month. The laboratory examination revealed pancytopenia and the peripheral blood smear examination revealed blast cells. On flow cytometric analysis, the blast cells were found to be positive for cytoplasmic CD3, CD2, CD5, CD7, CD34, CD56, CD33 and CD117, and negative for myeloperoxidase, CD13, CD11b, CD15, CD19, CD79a, CD22 and CD10. The patient was diagnosed with T‑cell ALL according to the 2008 World Health Organisation classification. The patient did not respond to Hyper‑cyclophosphamide, vincristine, adriamycin and dexamethasone (CVAD) course A treatment and succumbed to the disease during Hyper‑CVAD course B treatment. To the best of our knowledge, this is the first report of aberrant co‑expression of the natural killer cell marker CD56, myeloid cell markers CD117 and CD33 and stem cell marker CD34 in a patient with T‑cell ALL. This appears to be associated with an unfavorable outcome, despite the use of intensive chemotherapy.
View References
|
1
|
Van Vlierberghe P and Ferrando A: The
molecular basis of T-cell acute lymphoblastic leukemia. J Clin
Invest. 122:3398–3406. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gamal AH: Classification of Acute
Leukemia. University of Aden/Hematology unit. Yemen: 2011.
|
|
3
|
Supriyadi E, Veerman AJ Sutaryo, Purwanto
I, Vd Ven PM and Cloos J: Myeloid antigen expression in childhood
acute lymphoblastic leukemia and its relevance for clinical outcome
in indonesian ALL-2006 protocol. J Oncol. 2012:1351862012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suggs JL, Cruse JM and Lewis RE: Aberrant
myeloid marker expression in precursor B-cell and T-cell leukemias.
Exp Mol Pathol. 83:471–473. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uckun FM, Sather HN, Gaynon PS, Arthur DC,
Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG and
Reaman GH: Clinical features and treatment outcome of children with
myeloid antigen-positive acute lymphoblastic leukemia: A report
from the Children's cancer group. Blood. 90:28–35. 1997.PubMed/NCBI
|
|
6
|
Montero I, Rios E, Parody R, Perez-Hurtado
JM, Martin-Noya A and Rodriguez JM: CD56 in T-cell acute
lymphoblastic leukaemia: A malignant transformation of an early
myeloid-lymphoid progenitor? Haematologica. 88:ELT262003.PubMed/NCBI
|
|
7
|
Fischer L, Gökbuget N, Schwartz S,
Burmeister T, Rieder H, Brüggemann M, Hoelzer D and Thiel E: CD56
expression in T-cell acute lymphoblastic leukemia is associated
with non-thymic phenotype and resistance to induction therapy but
no inferior survival after risk-adapted therapy. Haematologica.
94:224–229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the world health organization (WHO) classification of
myeloid neoplasms and acute leukemia: Rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pui CH, Hancock ML, Head DR, Rivera GK,
Look AT, Sandlund JT and Behm FG: Clinical significance of CD34
expression in childhood acute lymphoblastic leukemia. Blood.
82:889–894. 1993.PubMed/NCBI
|
|
10
|
Vitale A, Guarini A, Ariola C, Mancini M,
Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, et al:
Adult T-cell acute lymphoblastic leukemia: Biologic profile at
presentation and correlation with response to induction treatment
in patients enrolled in the GIMEMA LAL 0496 protocol. Blood.
107:473–479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhushan B, Chauhan PS, Saluja S, Verma S,
Mishra AK, Siddiqui S and Kapur S: Aberrant phenotypes in childhood
and adult acute leukemia and its association with adverse
prognostic factors and clinical outcome. Clin Exp Med. 10:33–40.
2010. View Article : Google Scholar : PubMed/NCBI
|
